Trial Profile

A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tasimelteon (Primary)
Indications Circadian rhythm sleep disorders
Focus Registrational; Therapeutic Use
Acronyms RESET
Sponsors Vanda Pharmaceuticals

Most Recent Events

06 Aug 2015 Results of two trials (SET and RESET) published online in the Lancet.
05 Aug 2015 According to a Vanda Pharmaceuticals media release, this and SET trial led to approval with the European marketing authorization for Hetlioz.
05 Aug 2015 Results published in the Vanda Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com